News

AX-0810, an experimental medication Proqr Therapeutics is developing for biliary atresia and another liver disease called primary sclerosing cholangitis (PSC), is about to…

Kezar Life Sciences has hit a roadblock in plans to develop zetomipzomib, its experimental treatment for autoimmune hepatitis (AIH). The company has…

Health Canada has conditionally approved Gilead Sciences’ seladelpar — to be marketed in the country under the brand name Lyvdelzi — as a second-line…

Itching was the main symptom leading to the diagnosis of progressive familial intrahepatic cholestasis (PFIC) type 3 in a teenage boy in Portugal, a…

A new dataset from genomics company Helix aims to accelerate research into metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease.

Treatment with Livmarli (maralixibat) quickly and safely reduced severe itching in a 16-year-old boy with Alagille syndrome after his transplanted liver started to malfunction,…

A Phase 1 clinical trial testing PBGENE-HBV, a gene-editing therapy for chronic hepatitis B, is now recruiting patients at Massachusetts General Hospital in…

Women with primary biliary cholangitis (PBC) may be at increased risk of having disease flares in the months following childbirth, according to a small…

Agrimonolide, a molecule found in a traditional Chinese herb, eased liver damage, scarring, and inflammation in a mouse model of cholestasis, a study showed.

The first healthy volunteers have been dosed in a Phase 1 clinical trial testing a combination therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form…